AstraZeneca PLC Ordinary Shares (AZN)
R&D Expense Growth
16.07%
Quarterly · Period ending:
AZN R&D Expense Growth
Latest reported16.07%period ending
Latest reported16.07%period ending
AZN Quarterly R&D Growth (QoQ) (0.00% → 16.07%)
Latest values, visible window
High-resolution chart · PNG
AZN r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -0.1228% | |
| -36.5686% | |
| 68.0222% | |
| 2.3699% | |
| 2.9678% | |
| -36.9443% | |
| 42.404% | |
| 1.2195% | |
| 0% | |
| 0% | |
| 0% | |
| -100% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |